NCT07291076ClinicalTrials.gov ↗
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
NCT06096779Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
NCT07284121ClinicalTrials.gov ↗
This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
NCT06921785ClinicalTrials.gov ↗
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
NCT07391670ClinicalTrials.gov ↗
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).
About the trial
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak wątroby w zaawansowanym stadium, którego nie można leczyć operacyjnie ani innymi miejscowymi terapiami.
- •Brak wcześniejszego leczenia ogólnego (w tym eksperymentalnymi lekami) na raka wątroby w zaawansowanym stadium.
- •Rak wątroby widoczny na badaniach obrazowych (przynajmniej jedna zmiana docelowa, która nie była leczona).
- •Stan ogólny pacjenta pozwala na udział w badaniu (zgodnie ze skalą ECOG 0-2).
- •Marskość wątroby typu Child-Pugh B7 lub B8.
- •Odpowiednia liczba komórek krwi i prawidłowe funkcjonowanie narządów.
- •Przewidywana długość życia co najmniej 12 tygodni.
- •Kobiety w wieku rozrodczym muszą zgadzać się na unikanie ciąży i oddawania komórek jajowych.
✗ Disqualifies
- •Ciąża lub karmienie piersią.
- •Wcześniejsze leczenie lekami wpływającymi na układ odpornościowy (np. agonisty CD137 lub terapie blokujące punkty kontrolne).
- •Przyjmowanie jakichkolwiek innych leków eksperymentalnych w ciągu ostatnich 28 dni.
- •Przeszłe leczenie wątroby metodami miejscowymi (np. wstrzyknięcia, embolizacja) w ciągu ostatnich 28 dni.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (54)
University of Arizona Cancer Center
Tucson, United States
UC San Diego Moores Cancer Center
La Jolla, United States
University of Southern California-Keck School of Medicine -1975 Zonal Ave
Los Angeles, United States
University of Southern California
Newport Beach, United States
University of California Irvine Medical Center
Orange, United States
California Liver Research Institute
Pasadena, United States
University of California Davis Medical Center
Sacramento, United States
Stanford Health Care
Stanford, United States
Harbor UCLA Medical Center
Torrance, United States
Cedars Sinai Comprehensive Transplant Center
West Hollywood, United States
Hartford Healthcare Cancer Institute at Hartford Hospital
Hartford, United States
George Washington University- Medical Faculty Associates
Washington D.C., United States
Washington DC VA Medical Center
Washington D.C., United States
Orlando Health Inc.
Orlando, United States
Northwestern University
Chicago, United States
University of Illinois Health Outpatient Care Center
Chicago, United States
The Duchossois Center for Advanced Medicine
Chicago, United States
University of Kentucky - Markey Cancer Center
Lexington, United States
LSU Health Baton Rouge
Baton Rouge, United States
Our Lady of the Lake Cancer Institute
Baton Rouge, United States
Tufts Medical Center
Boston, United States
Beth Israel Deaconess Medical Center
Boston, United States
Barbara Ann Karmanos Cancer Institute
Detroit, United States
Henry Ford Health System
Detroit, United States
Saint Luke?s Hospital of Kansas City
Kansas City, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Rutgers Cancer Institute of New Jersey at University Hospital
Newark, United States
NYU Langone Hospital - Long Island
Mineola, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Montefiore Medical Center
The Bronx, United States
James J Peters Veterans Administration Medical Center - NAVREF
The Bronx, United States
Levine Cancer Institute
Charlotte, United States
Dayton VA Medical Center - NAVREF - PPDS
Dayton, United States
The University of Oklahoma Health Sciences Center
Oklahoma City, United States
Kaiser Permanente Westside Medical Center
Hillsboro, United States
OHSU Knight Cancer Institute Hematology Oncology
Portland, United States
Jefferson Health Honickman Center
Philadelphia, United States
Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
Pittsburgh, United States
The West Clinic (East Campus)
Germantown, United States
Nashville General Hospital at Meharry
Nashville, United States
Liver Institute at Methodist Dallas
Dallas, United States
Moody Outpatient Center ? Parkland Health
Dallas, United States
Texas Oncology (Worth) - USOR
Dallas, United States
University of Texas Southwestern Medical Center
Dallas, United States
Texas Oncology - Denison Cancer Center
Denison, United States
Kelsey Research Foundation
Houston, United States
Michael E Debakey VA Medical Center - NAVREF - PPDS
Houston, United States
Intermountain Healthcare
Murray, United States
Intermountain Cancer Center
St. George, United States
Inova Schar Cancer Institute
Falls Church, United States
Bon Secours St. Mary's Hospital
Richmond, United States
VCU Medical Center North Hospital
Richmond, United States
Virginia Mason Medical Center
Seattle, United States
Pan American Center for Oncology Trials, LLC
Rio Piedras, Puerto Rico
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.